The role of Zinc L-Carnosine in the prevention and treatment of gastrointestinal mucosal disease in humans: a review.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or original patient data.
PubMed 35659631 · doi:10.1016/j.clinre.2022.101954
What was done
This paper is a narrative review summarizing the pharmacological mechanisms and clinical applications of zinc L-carnosine for the prevention and treatment of gastrointestinal mucosal diseases in humans. The abstract describes no systematic search methodology, inclusion criteria, or quantitative synthesis methods.
What was found
The abstract provides no numerical data, sample sizes, or effect estimates. It reports qualitatively that zinc L-carnosine provides cytoprotective and anti-inflammatory actions through antioxidant effects, cytokine modulation, and membrane stabilization, driven by affinity for damaged mucosa and local zinc release. Applications identified include peptic ulcer disease, chemoradiotherapy-induced oral mucositis and esophagitis, ulcerative colitis, post-endoscopy ulcers, hemorrhoidal disease, and impaired intestinal permeability.
Why it matters
It provides clinicians and researchers with an overview of the biological rationale and broad clinical scope of zinc L-carnosine as a direct mucosal repair agent.
Limits
The review appears narrative rather than systematic, leaving it prone to selection bias. The abstract presents no quantitative efficacy figures, comparative trial data, or safety profiles to determine the strength of evidence for any specific clinical indication.
Cited by
- supports Zinc carnosine supports and improves the integrity of the gastrointestinal mucosal lining.